Advertisement
UK markets closed

  • FTSE 100

    8,275.38
    +44.33 (+0.54%)
     

  • FTSE 250

    20,730.12
    +59.25 (+0.29%)
     

  • AIM

    805.79
    +3.10 (+0.39%)
     

  • GBP/EUR

    1.1742
    -0.0007 (-0.06%)
     

  • GBP/USD

    1.2738
    +0.0006 (+0.05%)
     

  • Bitcoin GBP

    53,081.40
    +295.59 (+0.56%)
     

  • CMC Crypto 200

    1,423.69
    -4.88 (-0.34%)
     

  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     

  • DOW

    38,686.32
    +574.84 (+1.51%)
     

  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     

  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     

  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     

  • HANG SENG

    18,079.61
    -150.58 (-0.83%)
     

  • DAX

    18,497.94
    +1.15 (+0.01%)
     

  • CAC 40

    7,992.87
    +14.36 (+0.18%)
     
PROPERTY:

10 bijou homes that are big on style

Size isn’t everything when it comes to buying a home

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

LAVA Therapeutics N.V.
·2-min read
LAVA Therapeutics N.V.
LAVA Therapeutics N.V.

UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2)

T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference.

Presentation Details
Format: Fireside Chat
Date: Monday, May 13, 2024
Time: 10:00 a.m. ET

A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news-events/events. The replay will be archived for 90 days following the presentation date.

ADVERTISEMENT

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens.

A Phase 1/2a dose escalation trial (NCT05369000) to evaluate the lead program, LAVA-1207, in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States in a trial evaluating monotherapy and with interleukin-2 (IL-2). The Company is also expanding the Phase 1/2a study to include a combination arm with KEYTRUDA®(pembrolizumab), through a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA. The Company licensed PF-08046052 (formerly LAVA-1223) to Pfizer Inc. for clinical development and commercialization. The pipeline also includes several pre-clinical programs. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, X, and YouTube.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. LLC, Rahway, NJ, USA

Gammabody® is a registered trademark of LAVA Therapeutics N.V.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

LifeSci Advisors (IR/Media)
Joyce Allaire
Jallaire@lifesciadvisors.com